Catalyst Pharmaceuticals, Inc. (CPRX) on Decifer

Decifer ranks CPRX number 51 of 277 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 20% and it turns most of its profit into real cash.
• Revenue is growing about 20% a year and profits grew 27% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• And it returns cash to shareholders.
• Strong returns around 20% with revenue up about 20% a year and momentum of 20 out of 35 make this a solid business, but no stated reason to grow caps it.

The current read

The evidence on CPRX lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Catalyst Pharmaceuticals, Inc. operates in biotechnology. That places it inside the Healthcare, Biotech & Devices story.

Read the full CPRX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.